Skip to main content

Table 1 Baseline characteristics of study population

From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19

Characteristic Total
(n = 3,788)
Hypertension
(n = 1,190)
Non-hypertension (n = 2,598) P-value
Age (yr) 52.1 ± 15.1 63.9 ± 14.0 46.7 ± 12.3 < 0.001
Age distribution (yr)     < 0.001
30‒39 970 (25.6) 57 (4.8) 913 (35.1)  
40‒49 860 (22.7) 142 (11.9) 718 (27.6)  
50‒59 808 (21.3) 259 (21.8) 549 (21.1)  
60‒69 570 (15.0) 289 (24.3) 281 (10.8)  
70‒79 374 (9.9) 271 (22.8) 103 (4.0)  
80–89 180 (4.8) 151 (12.7) 29 (1.1)  
≥ 90 26 (0.7) 21 (1.8) 5 (0.2)  
Male sex 1,692 (44.7) 605 (50.8) 1,087 (41.8) < 0.001
Comorbidity     
Diabetes 655 (17.3) 483 (40.6) 172 (6.6) < 0.001
Dyslipidemia 1,103 (29.1) 716 (60.2) 387 (14.9) < 0.001
Chronic kidney disease 234 (6.2) 213 (18.0) 21 (0.8) < 0.001
Chronic obstructive pulmonary disease 387 (10.2) 213 (18.0) 174 (6.7) < 0.001
Cancer 313 (8.3) 153 (12.9) 160 (6.2) < 0.001
Cardiovascular disease 513 (13.5) 429 (36.1) 84 (3.2) < 0.001
Ischemic heart disease 269 (7.1) 226 (19.0) 43 (1.7) < 0.001
Myocardial infarction 36 (1.0) 34 (2.9) 2 (0.1) < 0.001
Stroke 185 (4.9) 163 (13.7) 22 (0.8) < 0.001
Congestive heart failure 223 (5.9) 191 (16.1) 32 (1.2) < 0.001
  1. Data are presented as mean ± standard deviation or number (%)